1 (currently amended). A compound having the formula I



I

in which:

Ring A is (C_3-C_8)-cycloalkanediyl or (C_3-C_8)-cycloalkenediyl~~, wherein one or more carbon atoms of the (C_3-C_8)-cycloalkanediyl ring or the (C_3-C_8)-cycloalkenediyl ring may be replaced by oxygen atoms~~;

R1, R2 independently of one another are H, F, Cl, Br, CF_3, OCF_3, (C_1-C_8)-alkyl, O-(C_1-C_8)-alkyl, SCF_3, SF_5, OCF_2-CHF_2, (C_6-C_{10})-aryl, (C_6-C_{10})-aryloxy, OH, NO_2; or

R1 and R2 together with the phenyl~~, pyridine, 1H-pyrrole, thiophene or furan~~ ring form fused, partially or unsaturated bicyclic (C_6-C_{10})-aryl[[,]] ~~(C_8-C_{14})-heteroaryl~~;

R3 is H, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, (C_1-C_3)-alkyl-(C_3-C_8)-cycloalkyl, phenyl, (C_1-C_3)-alkyl-phenyl, ~~(C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl~~ or (C1-C3)-alkyl which is fully or partially substituted by F;

W is CH ~~or N if o = 1~~;

o is 1;

~~W is O, S or NR10 if o = 0;~~

X is (C_1-C_6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;

n is 0-2;

R4 is H or (C_1-C_6)-alkyl;

R5 is H or (C_1-C_6)-alkyl;

R6 is H, (C_1-C_6)-alkyl or F;

R7 is H; F; (C_1-C_6)-alkoxy; (C_2-C_6)-alkenyl; (C_2-C_6)-alkynyl; (C_3-C_8)-cycloalkyl; phenyl which may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, (C_1-C_6)-alkoxy, F and CF_3; (C_1-C_6)-alkyl which may be unsubstituted or substituted by one or more radicals selected from the group consisting of hydroxyl, phenyl, ~~(C_5-C_{11})-heteroaryl,~~ (C_1-C_6)-alkoxy and NR11R12;

with the proviso that R7 is not NR11R12 or (C_1-C_6)-alkoxy if R6 = F;

R7 and R9 together with the atoms that carry them are pyrrolidine ~~or piperidine~~ if n = 0;

R6 and R7 together with the carbon atom that carries them are (C_3-C_8)-cycloalkyl;

R8 is H, (C_1-C_6)-alkyl;

R9 is H, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_1-C_4)-alkyl-(C_6-C_{10})-aryl, ~~(C_4-C_4)-alkyl-(C_5-C_{11})-heteroaryl,~~ (C_1-C_4)-alkyl-O-(C_1-C_4)-alkyl, phenyl-(C_1-C_4)-alkyl, ~~(C_5-C_6)-heteroaryl-(C_1-C_4)-alkyl~~;

R10 is H, (C_1-C_6)-alkyl-phenyl, (C_1-C_6)-alkyl;

R11 is H, (C_1-C_6)-alkyl-phenyl, (C_1-C_6)-alkyl;

R12 is H, (C_1-C_6)-alkyl-phenyl, (C_1-C_6)-alkyl;

a physiologically acceptable salt of the compound;
a solvate of the compound; or
a physiologically effective derivative of the compound.

2 (original). The compound of Claim 1, in which

Ring A is (C_3-C_8)-cycloalkanediyl or (C_3-C_8)-cycloalkenediyl, wherein one carbon

atom of the (C_3-C_8)-cycloalkanediyl ring or the (C_3-C_8)-cycloalkenediyl ring may be replaced by an oxygen atom;

X is (C_1-C_6)-alkanediyl, wherein the C1 or C2 carbon atom (to Ring A) of the alkanediyl group may be replaced by an oxygen atom.

3 (currently amended). The compound of Claim 1, in which

Ring A is cis-cyclohexane-1,3-diyl

R1 is Br, CF_3, OCF_3, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl;

R2 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl or

R1 and R2 together with the phenyl ring form naphthyl;

R3 is CF_3, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, phenyl;

W is CH ~~if o = 1~~;

o is 1;

X is CH_2O or CH_2-O-CH_2;

n is 0;

R6 is H or (C_1-C_6)-alkyl;

R7 is (C_1-C_6)-alkyl, where alkyl may be unsubstituted or substituted by phenyl;

R7 and R9 together with the atoms that carry them are pyrrolidine if n = 0;

R6 and R7 together with the carbon atom that carries them are (C_3-C_6)-cycloalkyl;

R8 is H; and

R9 is H, (C_1-C_6)-alkyl or benzyl.

4 (original). A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

5(original). The pharmaceutical composition of Claim 4, further comprising an active compound having a favorable effect on a metabolic disorder or disease.

6 (original). The pharmaceutical composition of Claim 4, further comprising an antidiabetic.

7 (original). The pharmaceutical composition of Claim 4, further comprising a lipid modulator.

8 (withdrawn). A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

9 (withdrawn). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

10 (withdrawn). A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

11 (withdrawn). A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

12 (withdrawn). A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

13 (withdrawn). The method of Claim 8, further comprising administering in combination at least one further active compound for treating and/or preventing a disorder of the fatty acid metabolism and/or glucose utilization disorder.

14 (withdrawn). The method of Claim 9, further comprising administering a at least one further active compound for treating and/or preventing a disorder in which insulin is involved.

15 (withdrawn). A process for preparing a pharmaceutical comprising the compmound of Claim 1, comprising the steps of:

(a) mixing the compound with a pharmaceutically acceptable carrier, and;

(b) bringing the mixture into a form suitable for administration.

16 (original). A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.

17 (withdrawn). A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

18 (withdrawn). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

19 (withdrawn). A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

20 (withdrawn). A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

21 (withdrawn). A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

22 (original). A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.

23 (withdrawn). A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

24 (withdrawn). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

25 (withdrawn). A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

26 (withdrawn). A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

27 (withdrawn). A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.